{
  "id": "ctla-four",
  "title": "CTLA-4",
  "lang": "en",
  "source_lang": "en",
  "summary": "CTLA-4 is an inhibitory receptor on T cells that limits immune activation, maintains self-tolerance, and serves as a target for cancer immunotherapy and immune-modulating drugs.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [
    "Cytotoxic T-lymphocyte-associated protein 4",
    "Cytotoxic T-lymphocyte antigen 4",
    "CD152"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/ctla-four/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/ctla-four/",
      "json": "https://aiwiki.page/zh/ctla-four.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also designated CD152, is a cell-surface protein that restrains T-cell activation. It functions as an immune checkpoint by limiting the costimulatory signals required for many T-cell responses. Encoded by the human CTLA4 gene, it is particularly important in regulatory T cells and in maintaining peripheral immune tolerance. Drugs that block CTLA-4 can strengthen antitumor immunity, whereas drugs that mimic its ligand-binding activity can suppress immune activation."
    },
    {
      "heading": "Molecular structure and expression",
      "text": "The human CTLA4 gene lies on chromosome 2, near genes encoding the related immune receptors CD28 and ICOS. Its principal protein product is a type I transmembrane glycoprotein: an extracellular immunoglobulin-like domain binds other proteins, a membrane-spanning segment anchors the receptor, and a short cytoplasmic tail regulates trafficking and interactions inside the cell. CTLA-4 commonly forms a disulfide-linked homodimer.\n\nCTLA-4 belongs to the same receptor family as CD28, but the two have contrasting functions. CD28 promotes T-cell activation, while CTLA-4 restricts the availability and effects of the signals that CD28 receives.\n\nIn conventional resting T cells, CTLA-4 expression is generally low and increases after activation. Regulatory T cells express it constitutively, although much of the protein is stored in intracellular compartments rather than exposed on the cell membrane. Rapid delivery to the surface, internalization, and recycling help determine where and when CTLA-4 can act. Consequently, total cellular abundance does not directly indicate how much functional receptor is available at the cell surface."
    },
    {
      "heading": "Role in T-cell activation",
      "text": "Competition for costimulatory ligands\n\nT-cell activation usually requires more than recognition of an antigen. The T-cell receptor recognizes a peptide presented by a major histocompatibility complex molecule. Additional signals, including T-cell costimulation, help determine whether recognition produces an effective response.\n\nA major costimulatory pathway involves CD28 binding to CD80 or CD86, also called B7-1 and B7-2. These ligands occur on antigen-presenting cells, including dendritic cells and activated B cells.\n\nCTLA-4 binds the same two ligands, generally with greater affinity and avidity than CD28. It can therefore compete for ligand engagement and reduce CD28-mediated costimulation. This limits T-cell proliferation and the production of activation-associated mediators such as interleukin-2. The outcome depends on receptor and ligand abundance, their organization at cell contacts, and the activation state of the interacting cells.\n\nRemoval of ligands from other cells\n\nCTLA-4 also acts through trans-endocytosis. A CTLA-4-expressing T cell can capture CD80 or CD86 from the membrane of an interacting antigen-presenting cell and internalize the captured material for degradation.\n\nThis mechanism changes the antigen-presenting cell itself: fewer costimulatory ligands remain available to stimulate other T cells. CTLA-4 can therefore suppress responses beyond the cell carrying the receptor. This cell-extrinsic activity is especially important in regulatory T-cell function.\n\nIntracellular effects\n\nCTLA-4 engagement has also been associated with changes in signaling within T cells. Its cytoplasmic tail supports interactions involved in receptor trafficking and the regulation of activation pathways, despite lacking intrinsic enzymatic activity.\n\nThe relative contributions of intracellular signaling, competition with CD28, and ligand removal vary across experimental settings. CTLA-4 is therefore not adequately described simply as an intracellular “off switch”; regulation of interactions between cells is central to its activity."
    },
    {
      "heading": "Immune tolerance and biological importance",
      "text": "CTLA-4 helps prevent excessive responses to the body's own tissues and limits the expansion of activated T cells. It complements, rather than replaces, other mechanisms of immune tolerance, including the elimination of strongly self-reactive developing T cells and suppression by regulatory T cells.\n\nIts importance is evident in experimental animals: mice lacking functional CTLA-4 develop severe lymphocyte proliferation, widespread tissue infiltration, and early fatal immune disease. These findings established CTLA-4 as an essential regulator of immune homeostasis rather than merely a modest modifier of activation.\n\nCTLA-4 should not be equated with a marker of a single T-cell state. It is expressed by activated conventional T cells as well as regulatory T cells, and its presence alone does not establish that a cell is exhausted, suppressive, or incapable of responding."
    },
    {
      "heading": "Genetic deficiency and immune dysregulation",
      "text": "Heterozygous loss-of-function variants in CTLA4 can cause CTLA-4 haploinsufficiency, a disorder of immune regulation. Reported manifestations include autoimmune destruction of blood cells, lymphocyte accumulation, intestinal inflammation, recurrent infections, and reduced circulating immunoglobulins. Expression is variable: some carriers have substantial disease, whereas others have few or no recognized manifestations.\n\nA related disorder results from deficiency of LRBA, a protein involved in intracellular trafficking. LRBA helps protect CTLA-4 from degradation and supports its recycling. LRBA deficiency can therefore reduce functional CTLA-4 availability even when the CTLA4 gene itself is intact.\n\nThese disorders illustrate why loss of an inhibitory pathway does not necessarily produce uniformly stronger protective immunity. Poorly regulated activation can coexist with impaired antibody responses and susceptibility to infection.\n\nCommon variation near CTLA4 has also been associated with susceptibility to several autoimmune diseases. Such associations differ from rare disease-causing variants and do not, by themselves, establish an individual's clinical outcome."
    },
    {
      "heading": "Therapeutic applications",
      "text": "CTLA-4 blockade in cancer\n\nBlocking CTLA-4 with an antibody can increase immune responses against cancer. Ipilimumab became the first approved CTLA-4-blocking antibody in 2011, initially for advanced melanoma. Tremelimumab is another CTLA-4-blocking antibody used in approved combination regimens for selected cancers.\n\nThese drugs reduce inhibitory control over T-cell responses. Their antitumor effects can involve changes in T-cell priming and in the tumor immune environment. The contribution of effects on regulatory T cells depends on the antibody and biological context.\n\nCTLA-4 blockade is also used in combination with drugs targeting other checkpoints, particularly the PD-1 pathway. The pathways overlap in their consequences but are not interchangeable.\n\nBecause CTLA-4 contributes to self-tolerance, blocking it can cause immune-related adverse events. These include inflammation of the intestine, liver, skin, and endocrine organs; severe and potentially fatal reactions can occur. Clinical benefit and toxicity vary by cancer, regimen, and patient population.\n\nCTLA-4–Ig fusion proteins\n\nA contrasting strategy uses the extracellular ligand-binding portion of CTLA-4 fused to an immunoglobulin Fc region. These CTLA-4–Ig proteins bind CD80 and CD86 and prevent their engagement with CD28, thereby reducing costimulation.\n\nAbatacept is used for certain inflammatory and autoimmune indications, including rheumatoid arthritis. Belatacept, a modified CTLA-4–Ig protein, is used to prevent rejection in eligible adult kidney-transplant recipients.\n\nThese agents do not activate CTLA-4 receptors on T cells. Instead, they reproduce part of CTLA-4's ligand-binding function. Their immunosuppressive effects contrast with the immune-enhancing purpose of CTLA-4-blocking antibodies."
    },
    {
      "heading": "Discovery and historical significance",
      "text": "CTLA-4 was identified in 1987 through studies of genes expressed in activated cytotoxic T cells. Its resemblance to CD28 initially left its function uncertain. Experiments in the mid-1990s established its inhibitory role, including studies showing severe immune dysregulation after gene deletion.\n\nSubsequent work demonstrated that CTLA-4 blockade could promote tumor rejection in experimental models, providing a foundation for clinical checkpoint immunotherapy. The 2018 Nobel Prize in Physiology or Medicine recognized James P. Allison and Tasuku Honjo for discoveries enabling cancer therapy through inhibition of negative immune regulation; Allison's contribution centered on CTLA-4."
    }
  ],
  "links": [
    "protein",
    "t-cell",
    "immune-checkpoint",
    "gene",
    "regulatory-t-cell",
    "peripheral-immune-tolerance",
    "cell-membrane",
    "antigen",
    "t-cell-receptor",
    "major-histocompatibility-complex",
    "t-cell-costimulation",
    "antigen-presenting-cell",
    "dendritic-cell",
    "b-cell",
    "interleukin-two",
    "immune-tolerance",
    "antibody",
    "cancer",
    "inflammation"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}